Coverage / MRK / Trade Card

MRK

Merck & Co Inc

SPECULATIVE BUY 2026-08-19 Data 24 days old USD 135.17 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
ACTIONABLEMethodology gates passed
46

Position levels

Currenttoday
USD 135.17
Buy <=wait / entry
USD 110.00
Trim >=take some off
USD 140.00
Thesis breakA material Complete Response Letter or clinical failure on a named late-stage on...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case11%100 / 10011.0
Base case51%62 / 10031.6
Bear case38%10 / 1003.8
Weighted conviction46 / 100 - SPECULATIVE BUY

Top risks

  • Raised full-year 2026 revenue guidance to $66.3-$67.3 billion despite Q2 net loss
  • R&D funding agreement with Blackstone Life Sciences for sac-TMT ($700 million) to advance 15 Phase 3 trials
  • Phase 3 INTerpath-001 trial announced with Moderna for Intismeran Autogene
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.